Indication
Shingles & PHN Pain: An Overview
Shingles is a painful infection caused by the same virus that causes chicken pox – the varicella zoster virus. Once a person has had chicken pox, the virus can lay dormant in the body for years before awakening later as shingles, a condition characterized by painful blisters on the skin.1
Approximately 95% of Americans have had chicken pox.2 Every year, approximately one million people develop shingles.2,3 With age, the incidence and prevalence of shingles increases.2Factors that increase the risk for shingles are advancing age with a weakened immune system, stress, and physical trauma.3
Post herpetic neuralgia (PHN), also referred to as after-shingles pain, is characterized by severe pain in the same place where the shingles rash occurred.2 PHN pain results from nerve damage caused by the shingles rash. One out of every 5 people who have had shingles may go on to develop after-shingles pain in the same area.2
In helping treat your shingles patients, you play a vital role in helping them understand PHN, their risk factors, and available treatment options. This site is dedicated to providing you with some tools to better educate yourself and your patients about this condition. Inside you will find:-
Provider-to-Patient Materials
Educational tools designed to help you start a conversation with your patients about PHN pain. What your PHN patients tell you about their pain can make a difference in their treatment.
-
LIDODERM® Webcast Series
A webcast series that provides relevant information pertaining to the management of PHN patients.
-
Request Materials
Provides you with the opportunity to request these and other educational materials, additional information about LIDODERM®, and a visit from one of our sales representatives.
- LIDODERM® is indicated for relief of pain associated with post-herpetic neuralgia. Apply only to intact skin.
Important Safety Information
- LIDODERM is contraindicated in patients with a history of sensitivity to local anesthetics (amide type) or any product component.
- Even a used LIDODERM patch contains a large amount of lidocaine (at least 665 mg). The potential exists for a small child or pet to suffer serious adverse effects from chewing or ingesting a new or used LIDODERM patch, although the risk with this formulation has not been evaluated. It is important for patients to store and dispose of LIDODERM out of reach of children, pets, and others.
- Excessive dosing, such as applying LIDODERM to larger areas or for longer than the recommended wearing time, could result in increased absorption of lidocaine and high blood concentrations leading to serious adverse effects.
- Avoid contact of LIDODERM with the eye. If contact occurs, immediately wash the eye with water or saline and protect it until sensation returns. Avoid the use of external heat sources as this has not been evaluated and may increase plasma lidocaine levels.
- Patients with severe hepatic disease are at greater risk of developing toxic blood concentrations of lidocaine, because of their inability to metabolize lidocaine normally. LIDODERM should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. LIDODERM should also be used with caution in pregnant (including labor and delivery) or nursing mothers.
- Allergic reactions, although rare, can occur.
- During or immediately after LIDODERM treatment, the skin at the site of application may develop blisters, bruising, burning sensation, depigmentation, dermatitis, discoloration, edema, erythema, exfoliation, irritation, papules, petechia, pruritus, vesicles, or may be the locus of abnormal sensation. These reactions are generally mild and transient, resolving spontaneously within a few minutes to hours. Other reactions may include dizziness, headache and nausea.
- When LIDODERM is used concomitantly with local anesthetic products, the amount absorbed from all formulations must be considered.
- Immediately discard used patches or remaining unused portions of cut patches in household trash in a manner that prevents accidental application or ingestion by children, pets, or others.
The following materials have been developed to provide you and your patients with a better understanding of shingles and PHN pain. Use these tools as a guide to gain knowledge and help facilitate a more robust patient dialogue regarding the treatment of after-shingles pain.
-
Wallboard
- Point-of-reference during counseling sessions when talking with your patients about shingles and PHN
- Serves as a "conversation starter" on the progression from chicken pox to shingles to PHN
- Guide to help patients pinpoint and describe their pain
-
Disease State Awareness Tool
& Takeaway
- Detailed explanation of the symptoms and risk factors associated with chicken pox, shingles, and PHN
- Used after a patient has been diagnosed with shingles or PHN
- Also provides an easy-to-understand brochure that patients can take home and use as a reference
-
Application and Usage Tool
& Takeaway
- Step-by-step teaching tool on how to properly apply, use, and then discard the LIDODERM patch
- Also provides PHN patients with an easy-to-understand guide that they can refer to at home when applying the patch
Indication
- LIDODERM® is indicated for relief of pain associated with post-herpetic neuralgia. Apply only to intact skin.
Important Safety Information
- LIDODERM is contraindicated in patients with a history of sensitivity to local anesthetics (amide type) or any product component.
- Even a used LIDODERM patch contains a large amount of lidocaine (at least 665 mg). The potential exists for a small child or pet to suffer serious adverse effects from chewing or ingesting a new or used LIDODERM patch, although the risk with this formulation has not been evaluated. It is important for patients to store and dispose of LIDODERM out of reach of children, pets, and others.
- Excessive dosing, such as applying LIDODERM to larger areas or for longer than the recommended wearing time, could result in increased absorption of lidocaine and high blood concentrations leading to serious adverse effects.
- Avoid contact of LIDODERM with the eye. If contact occurs, immediately wash the eye with water or saline and protect it until sensation returns. Avoid the use of external heat sources as this has not been evaluated and may increase plasma lidocaine levels.
- Patients with severe hepatic disease are at greater risk of developing toxic blood concentrations of lidocaine, because of their inability to metabolize lidocaine normally. LIDODERM should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. LIDODERM should also be used with caution in pregnant (including labor and delivery) or nursing mothers.
- Allergic reactions, although rare, can occur.
- During or immediately after LIDODERM treatment, the skin at the site of application may develop blisters, bruising, burning sensation, depigmentation, dermatitis, discoloration, edema, erythema, exfoliation, irritation, papules, petechia, pruritus, vesicles, or may be the locus of abnormal sensation. These reactions are generally mild and transient, resolving spontaneously within a few minutes to hours. Other reactions may include dizziness, headache and nausea.
- When LIDODERM is used concomitantly with local anesthetic products, the amount absorbed from all formulations must be considered.
- Immediately discard used patches or remaining unused portions of cut patches in household trash in a manner that prevents accidental application or ingestion by children, pets, or others.
LIDODERM® Webcast Series
Indication
- LIDODERM® is indicated for relief of pain associated with post-herpetic neuralgia. Apply only to intact skin.
Important Safety Information
- LIDODERM is contraindicated in patients with a history of sensitivity to local anesthetics (amide type) or any product component.
- Even a used LIDODERM patch contains a large amount of lidocaine (at least 665 mg). The potential exists for a small child or pet to suffer serious adverse effects from chewing or ingesting a new or used LIDODERM patch, although the risk with this formulation has not been evaluated. It is important for patients to store and dispose of LIDODERM out of reach of children, pets, and others.
- Excessive dosing, such as applying LIDODERM to larger areas or for longer than the recommended wearing time, could result in increased absorption of lidocaine and high blood concentrations leading to serious adverse effects.
- Avoid contact of LIDODERM with the eye. If contact occurs, immediately wash the eye with water or saline and protect it until sensation returns. Avoid the use of external heat sources as this has not been evaluated and may increase plasma lidocaine levels.
- Patients with severe hepatic disease are at greater risk of developing toxic blood concentrations of lidocaine, because of their inability to metabolize lidocaine normally. LIDODERM should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. LIDODERM should also be used with caution in pregnant (including labor and delivery) or nursing mothers.
- Allergic reactions, although rare, can occur.
- During or immediately after LIDODERM treatment, the skin at the site of application may develop blisters, bruising, burning sensation, depigmentation, dermatitis, discoloration, edema, erythema, exfoliation, irritation, papules, petechia, pruritus, vesicles, or may be the locus of abnormal sensation. These reactions are generally mild and transient, resolving spontaneously within a few minutes to hours. Other reactions may include dizziness, headache and nausea.
- When LIDODERM is used concomitantly with local anesthetic products, the amount absorbed from all formulations must be considered.
- Immediately discard used patches or remaining unused portions of cut patches in household trash in a manner that prevents accidental application or ingestion by children, pets, or others.
Fill out the fields below to request LIDODERM® samples.
You can also sign up to receive newsletters and get the additional information about LIDODERM.
We Respect Your Privacy
Endo Pharmaceuticals is committed to respecting the privacy of its Website visitors. We recognize the need to balance legitimate business interests in collecting and using information received from and about you with your reasonable expectations of privacy.
Aggregate Data
The Website may deposit certain bits of information called "cookies" in a visitor's computer. Cookies can tell us how and when pages in a website are visited and by how many people. This technology does not collect an individual visitor's identifying information. Rather, this information is in an aggregate form. The purpose of this technology and the information it provides is to help us to improve our websites.
Personally Identifiable Information
Endo Pharmaceuticals collects personally identifiable information, such as names, addresses, email addresses and the like, only when voluntarily provided by a Website visitor. Where visitors choose to provide the site with a name, email address or other information in order to receive email notices of new postings or other materials that may be offered, Endo keeps all such response lists confidential. In some instances, this information may be shared with entities that are acting on behalf of Endo Pharmaceuticals.
Indication
- LIDODERM® is indicated for relief of pain associated with post-herpetic neuralgia. Apply only to intact skin.
Important Safety Information
- LIDODERM is contraindicated in patients with a history of sensitivity to local anesthetics (amide type) or any product component.
- Even a used LIDODERM patch contains a large amount of lidocaine (at least 665 mg). The potential exists for a small child or pet to suffer serious adverse effects from chewing or ingesting a new or used LIDODERM patch, although the risk with this formulation has not been evaluated. It is important for patients to store and dispose of LIDODERM out of reach of children, pets, and others.
- Excessive dosing, such as applying LIDODERM to larger areas or for longer than the recommended wearing time, could result in increased absorption of lidocaine and high blood concentrations leading to serious adverse effects.
- Avoid contact of LIDODERM with the eye. If contact occurs, immediately wash the eye with water or saline and protect it until sensation returns. Avoid the use of external heat sources as this has not been evaluated and may increase plasma lidocaine levels.
- Patients with severe hepatic disease are at greater risk of developing toxic blood concentrations of lidocaine, because of their inability to metabolize lidocaine normally. LIDODERM should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. LIDODERM should also be used with caution in pregnant (including labor and delivery) or nursing mothers.
- Allergic reactions, although rare, can occur.
- During or immediately after LIDODERM treatment, the skin at the site of application may develop blisters, bruising, burning sensation, depigmentation, dermatitis, discoloration, edema, erythema, exfoliation, irritation, papules, petechia, pruritus, vesicles, or may be the locus of abnormal sensation. These reactions are generally mild and transient, resolving spontaneously within a few minutes to hours. Other reactions may include dizziness, headache and nausea.
- When LIDODERM is used concomitantly with local anesthetic products, the amount absorbed from all formulations must be considered.
- Immediately discard used patches or remaining unused portions of cut patches in household trash in a manner that prevents accidental application or ingestion by children, pets, or others.